CFG-920

DB19193InvestigationalSmall molecule

CFG-920 is under investigation in clinical trial NCT04060394 (Dose-escalation and Efficacy Study of Lae001/prednisone Plus Afuresertib Patients With M-crpc).

Chemical structure of CFG-920
Formula / weight
C14H13ClN4O · 288.74 g/mol (avg)
Also known as
1-(2-CHLORO-4-PYRIDINYL)-3-(4-METHYL-3-PYRIDINYL)-2-IMIDAZOLIDINONE · 2-imidazolidinone, 1-(2-chloro-4-pyridinyl)-3-(4-methyl-3-pyridinyl)-
Code names
CFG-920 · LAE-001

Resolves to

Compound
UNIIUP0K5026VBCAS1260006-20-9ChEMBLCHEMBL4297485
Structure
InChIKeyZVIFCOOHWGNPHJ-UHFFFAOYSA-NSMILESCC1=CC=NC=C1N1CCN(C1=O)C1=CC=NC(Cl)=C1
Targets
P05093CYP17A1

What you can answer from here — as of April 23, 2025

1Protein targetEach mapped to UniProt, with action and pharmacological action
Listed above
3Clinical trialsPhase, status and sponsor resolved per trial
Sign in
1+ReferenceStructured and connected to the statements they support
Sign in

Which drugs share a target with CFG-920, and which of those have an active Phase 3 trial?

Answer this in Biopharma OSSign in to your account

Create a free account or log in to explore the full data card.

Create Account
Log InPaid Account Log In